Texas Cancer Agency Stops Grants

The Cancer Prevention and Research Institute of Texas has agreed to stop awarding new grants until it addresses concerns about the integrity of is review process.

Written byDan Cossins
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, KUEBIAt the written request of Texas governor Rick Perry (R), the state’s embattled $3 billion dollar cancer research funding agency this week announced a moratorium on new grants, reported ScienceInsider. The agency will award no more grants until it properly addresses continued concerns about the legitimacy of its review procedures.

The Cancer Prevention and Research Institute of Texas (CPRIT) has been in trouble since May 2012, when its chief scientific officer, the Nobel Prize-winning biochemist Alfred Gilman, announced he would quit over grave concerns about the integrity of the agency’s peer-review procedure. Gilman stepped down in October, and was quickly followed by the chair of the review council and scores of peer reviewers.

Two more top officials, including the agency’s executive director, Bill Gimson, have resigned in the past few weeks amid allegations about possible criminal activity involving a round of grants awarded to companies owned by Dallas businessman David Shanahan, a major campaign contributor to Texas Governor Perry and Lieutenant Governor David Dewhurst.

Following the commencement of a civil investigation, CPRIT this week received ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies